Implicit Bioscience
Home Company People Technology Strategy Contact
Leveraging products and finance to reduce risk and improve outcomes for patients and shareholders.

 

Our focus is on diseases which are modulated by the host immune response. We use a virtual biotech model to identify clinical-stage assets for high-value development which is designed to unlock major benefits for both patients and shareholders. Where possible, we leverage our investor capital with non-dilutive funding by directing our effort at disease targets with high national strategic value.

 

Please click here to listen to a Shareholders briefing 15 October 2008.

(Note this file is password protected. Please email your name, phone number and company name to info@implicitbioscience.com for access details)

Privacy Policy     |     Legal Notice